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• Light-based technologies currently are cost-effective and widely available in market 
• Photons can be used to inactivate SARS-CoV-2 in air, liquids and on surfaces 
• Phototherapy can also be used as an adjuvant to modulate the host immune system.  





The global dissemination of the novel coronavirus disease (COVID-19) has accelerated the 
need for the implementation of effective antimicrobial strategies to target the causative agent 
SARS-CoV-2. Light-based technologies have a demonstrable broad range of activity over 
standard chemotherapeutic antimicrobials and conventional disinfectants, negligible 
emergence of resistance, and the capability to modulate the host immune response. This 
perspective article identifies the benefits, challenges, and pitfalls of repurposing light-based 
strategies to combat the emergence of COVID-19 pandemic. 
 




The pandemic spread of the novel coronavirus disease (COVID-19), caused by the SARS-
CoV-2 virus, is a red-alert global health threat [1,2]. In December 2019, COVID-19 expanded 
from Wuhan throughout China and was then exported throughout the world [1-4]. So far, more 
than 1 million people have been diagnosed with COVID-19 infection, and many more are 
expected to be diagnosed within the coming months [5,6]. As the epidemic evolves, national 
and global organizations are facing an urgent need to coordinate and combat this unprecedented 
large-scale public health crisis [6]. 
 
The epidemiological features of COVID-19 (i.e., severity, full spectrum of disease, 
transmissibility) have not been fully dissected [7]. The consensus is that the risk for severe 
acute disease symptoms and death is higher among the elderly and the immunocompromised 
[8-10]. In severe cases, infected patients need to be transferred to intensive care units for 
tracheal intubation [11]. This phenomenon is particularly worrisome because it can overwhelm 
healthcare facilities during the epidemic peak [10-13]. 
 
The spread and persistence of SARS-CoV-2 in diverse environments, such as healthcare, 
community, and residential areas, underlines the urgency for developing effective 
decontamination approaches as the pandemic crisis evolves [14]. A successful disinfection 
strategy coupled with additional infection-prevention countermeasures may substantially 
reduce transmissibility amongst asymptomatic carriers, a feature that is considered pivotal in 
the rapid dissemination of SARS-CoV-2. New light-mediated disinfection protocols are 
currently validated in hospitals and healthcare facilities for surface, air, and water as well as 
personal protective equipment (PPE), including eyewear, N95 respirators, and masks. 
Additionally, photobiomodulation, a light-based anti-inflammatory therapy, may have direct 
palliative effects on patients suffering from the so-called ‘cytokine storm’ associated with 
severe COVID-19. This review examines the potential of light-based technologies to prevent 
COVID-19 infection and control its dissemination by direct viral inactivation and to treat 
COVID-19 by modulating the host immune system. The direct antimicrobial actions of solar 
and UV radiation, photodynamic therapy, antimicrobial blue light, and ultrafast pulsed lasers 
for disinfection or in vivo use are considered, and the application of photobiomodulation to 
stimulate the host to mount an anti-viral response is discussed.  
 
2. SARS-CoV-2 stability outside the human body  
SARS-CoV-2 is highly infectious [15] and transmission occurs through contaminated air, 
water, and surfaces, which plays a pivotal role in its unbridled dissemination. A recent study 
by van Doremalen and colleagues investigated the stability of SARS-CoV-2 in aerosols and on 
inanimate surfaces (e.g., glass, metal, plastic, or cardboard) that can act as important 
transmission vectors [16]. Their findings suggest that aerosol and fomite transmission of 
SARS-CoV-2 is likely, indicating that the virus can remain viable and infectious for hours in 
aerosols and up to days on surfaces. This is in agreement with a recent comparative analysis of 
22 studies looking at the persistence of a broader panel of human coronaviruses on inanimate 
surfaces [17] This study included prominent pathogenic coronavirus species such as Severe 
Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and 
endemic human coronaviruses (HCoV) and concluded that: 1) viruses can remain infectious 
from 2 hours to 9 days; 2) incubation temperature is critical, as some viruses can remain viable 
at 4°C for up to 28 days whereas at 30–40°C viral viability is reduced.  
3. Historical Milestones of Antimicrobial Light 
 
The microbicidal effects of light have been widely known for more than a century. In 1885, 
Duclaux experimented with several microbial species and concluded that “sunlight is the best, 
cheapest, and most universally applicable microbicidal agent that we have” [18]. As early as 
1877, Downes and Blunt observed that light could effectively kill a series of microorganisms 
and reported that this effect was dependent on light parameters such as intensity, duration (i.e., 
light dose) and that the shortest wavelengths (e.g., blue to ultraviolet light) were the most 
effective [19] The first report on the virucidal effects of UV radiation dates back to 1928 when 
Rivers and Gates used UV light to inactivate viral particles in suspension and proved the 
efficacy of the method through subsequent subcutaneous inoculation of rabbits [20]. 
 
In 1903, Niels Finsen was awarded the Nobel Prize in Physiology or Medicine for his 
contribution to the treatment of infectious diseases, especially cutaneous tuberculosis, using 
visible light [21,22]. Virtually at the same time, Herman Von Tappeiner and Oscar Raab 
discovered by accident that the use of fluorescent dyes could enhance the microbial killing 
effect of visible light via photodynamic reactions [22]. By the 1930s, germicidal low-pressure 
Mercury (Hg) discharge lamps emitting quasi-monochromatic UV-C light (peak emission at 
254 nm) had been introduced into the market as highly efficient disinfection equipment [23]. 
Thus, since the pre-antibiotic era, light-based strategies have been extensively studied and used 
to treat and prevent infections [24]. However, each photoinactivation strategy has its pros and 
cons that must be carefully considered when designing a new microbial control strategy. 
 
4. Natural Ultraviolet Light  
 
Ultraviolet (UV) radiation is naturally and ubiquitously emitted by the sun, representing 10 % 
of its total light output. Only a small portion of the sunlight spectra has direct antimicrobial 
properties (UV-C). However, since most UV-C light is filtered by the atmospheric ozone layer, 
in practical terms, the antimicrobial activity associated with sunlight is mostly caused by 
photochemical reactions induced by UV-A and UV-B photons which are absorbed by 
endogenous chromophores such as amino acid residues, flavins, and porphyrin derivatives [25]. 
While UV-A alone does not seem to exert any significant virucidal effects, natural and artificial 
sunlight, as well as radiation in the UV-B spectrum, have been shown to inactivate 
bacteriophages and human viruses [26]. A model for the potential of solar UV radiation to 
inactivate viruses aerosolized in the atmosphere concluded that a full day of sun exposure 
would on average decrease the infectivity of UV-sensitive viruses by 3 log10 [27]. 
 
Besides its virucidal potential, solar UV radiation can also play a protective role against 
infectious diseases via its modulating effect on vitamin D production [28]. Vitamin D is known 
to upregulate the production of human cathelicidin, LL-37. This antimicrobial peptide has both 
antimicrobial and antiendotoxin activities, and also attenuates the production of 
proinflammatory cytokines which typically accompany respiratory tract infections. 
Accordingly, it was recently suggested that vitamin D could reduce the incidence, severity, and 
risk of death due to respiratory tract infections, notably those caused by COVID-19 [29]. 
However, conclusive evidence for an association between vitamin D supplementation and 
decreased risk of respiratory tract infections is still lacking. 
 
UV-C is directly absorbed by pyrimidine bases causing their dimerization, which leads to viral 
inactivation via DNA or RNA damage [30]. Thymine is the main chromophore in DNA while 
uracil is its counterpart in RNA. Upon UV-C exposure, thymine and uracil form cyclobutane-
dimers and pyrimidine-protein cross-links [30]. The viral protein coat has been shown to 
protect nucleic acids from UV-C radiation, by shielding the RNA, quenching the excited states 
of RNA, and/or by surrounding the bases with a hydrophobic environment and limiting the 
mobility of the individual bases. This results in a reduction of the overall rate of photoreactions, 
which allows the formation of non-cyclobutane-type dipyrimidines and uridine hydrates. Viral 
coating proteins themselves may suffer UV photodamage and become cross-linked to RNA. 
 
The International Ultraviolet Association (IUVA) recently released a fact sheet detailing the 
efficacy of UV on SARS-CoV-2 [31] in which they reviewed all the appropriate requirements 
for the safety of UV-C disinfection devices and discussed the corresponding performance 
standards and validation protocols. Coronaviruses display a wide range of UV-C LD90 (UV-C 
dose necessary to inactivate 90% of a microbial population) values, from 7 to 241 J/m2 so one 
might assume that the UV-C susceptibility of the novel SARS-CoV-2 (COVID-19) virus 
probably lies within this range [32]. Therefore, based on previous studies with SARS-CoV-1 
and other RNA-based coronaviruses, UV-C light can be used to effectively inactivate such 
pathogens present in the air, PPE, and on several types of surfaces [33,34]. 
 
5. Ultraviolet Germicidal Irradiation (UVGI)  
 
UV-C lamps have long been used in hospital and industrial settings for decontamination 
purposes. In the context of a mitigation approach to infection spreading, UV-C can be 
particularly helpful in the inactivation of virus-containing aerosols and surfaces.  
 
Air disinfection via upper-room germicidal UV-C light fixtures may be able to reduce viral 
transmission via the airborne route. Accordingly, an observational study during the 1957 
influenza pandemic reported that patients housed in hospital wards with upper-room UV-C had 
an infection rate of 1.9 %, compared to an infection rate of 18.9 % among patients housed in 
wards without UV-C [35]. However, it is important to note that the germicidal effect of UV-C 
seems to be strongly dependent on the relative humidity of the air, with UV-C effectiveness 
against influenza virus decreasing with increasing relative humidity [36]. 
 
The potential of viral spreading via contaminated surfaces depends on the ability of the virus 
to maintain infectivity in the environment, which in turn is influenced by several biological, 
physical, and chemical factors, including the type of virus, temperature, relative humidity, and 
type of surface [37]. A study that assessed the influence of genetic content and relative 
humidity on the virucidal effect of UV-C using viruses of different genetic composition 
concluded that single-stranded nucleic acid (ssRNA and ssDNA) viruses were more susceptible 
to UV inactivation than viruses with double-stranded nucleic acid (dsRNA and dsDNA) and 
that the UV dose necessary to achieve the same level of virus inactivation at 85 % relative 
humidity (RH) was higher than that at 55 % RH [37]. 
 
In an effort to safely expand the lifespan of the supply of medical equipment during the ongoing 
COVID-19 pandemic, it was estimated that 15-20 min exposure to 100 μW/cm2 of UV-C from 
a standard biosafety cabinet could efficiently disinfect N95 masks. The authors noted that this 
was an empirical estimation, with the proposed dose corresponding to 30 times the one 
necessary to inactivate 90 % of respiratory viruses. The widespread implementation of such a 
procedure could potentially reduce the current PPE burden by 75 % [38]. Even though UV 
does not seem to affect the filtrating capacity of N95 respirators, it is important to note that 
high UV-C doses can lead to reduced tensile strength of its materials [39]. 
 
Ultraviolet blood irradiation (UBI) is an alternative therapeutic application of UV-C [40]. This 
technique involves the extraction of a small proportion of the body’s total blood volume 
(typically 1-2 %), its irradiation with UV-C (254 nm) in a quartz tube followed by reinfusing 
it into the body. Rather than direct inactivation of pathogens, this procedure is thought to 
stimulate the host immune defense and has been used to treat both bacterial and viral infections, 
notably hepatitis [41]. 
 
The combination of multiple light wavelengths has been explored for cosmetic, environmental 
(water disinfection) and clinical (microbial catheter disinfection) applications. However, the 
precise photobiological mechanism of action and the experimental workflow to develop a 
marketable application is still missing [42,43]. 
 
It must be remarked that UV-C light at 254 nm can be harmful to the eyes and skin and, 
therefore, it is recommended to use it in setups that avoid direct human exposure. The use of 
far-UV-C (207-222 nm) has been proposed to minimize potential harm with human exposure 
[44]. This spectral range is strongly absorbed by amino acid residues and, therefore, is blocked 
by the acellular stratum corneum of the skin and the cornea of the eye, while still effective in 
the inactivation of viral particles and microbial cells present on surfaces and aerosols. However, 
this technology is still not broadly available in the market and the cost is far higher than 
common Hg lamps. UV-C LED technology is still limited to very compact applications. The 
shortest wavelengths available are around 250 nm, with the price per Watt being up to 1,000 
times higher than that Hg lamps, while displaying an energy efficiency (< 5 %) far lower than 
that of Hg lamps (25-40 %).  
 
6. Photoantimicrobials and Photodynamic Therapy  
 
Visible light can exert antiviral effects via photodynamic mechanisms that are initiated upon 
absorption of light by exogenous photosensitizer compounds, such as phenothiazinium salts, 
porphyrins, nanoparticles, and others [45-48]. The inactivation of microorganisms and viruses 
by visible light is based on the generation of lethal oxidant species via photosensitized 
oxidation reactions, which require three components: the chromophore, termed the 
photosensitizer (PS), light, and oxygen. After light absorption, excited oxygen states are 
quickly formed, initially in the singlet, and subsequently in the triplet states (i.e., considering 
the photocycle of organic molecules). These species can release the excitation energy in the 
form of light (e.g., fluorescence and phosphorescence) or heat (non-radiative decay) emission. 
Since excited states are intrinsically more reactive than ground states, energy and electron 
transfer reactions can occur. There are two main mechanisms of photosensitized oxidation: 
Type I reactions depend on the encounter of the excited species with biological substrates. 
These reactions usually occur through electron or hydrogen abstraction, leading to radical chain 
reactions; Type II reactions rely on energy transfer reaction from the PS triplet state to 




Light energy is thus converted into oxidation potential that can damage biomolecules. 
Antimicrobial photodynamic therapy (aPDT) is based on this process and it has been used to 
treat localized microbial infections caused by viruses, bacteria, fungi, and parasites [50]. 
Among the many pathogens that can be targeted by aPDT, viruses are perhaps the most 
vulnerable, as they depend on entering a host cell for survival and replication and can be 
inactivated by damaging the capsid or envelope molecules (lipids, carbohydrates, proteins) or 
internal molecules (nucleic acids) (Figure 1). Thus, many viruses can be treated via aPDT, 
including papillomavirus (HPV), hepatitis A virus (HAV), and herpes simplex virus (HSV) 
[51-53]. Additionally, the disinfection of biological fluids (plasma and blood products) by 
photoantimicrobials has been performed for decades and is a well-regarded technological 
application of these compounds. For instance, extracorporeal photoinactivation of 
coronaviruses and other clinically relevant pathogens using methylene blue (MB)-mediated 
aPDT has been reported [54-59].  
 
It is possible that photosensitized oxidation can neutralize SARS-CoV-2 and, consequently, 
play a role in mitigating the ongoing pandemic; however, there is no data available on the 
photodynamic inactivation of this virus. Thus, here we sought to find and discuss scientific 
literature that could help predict whether COVID-19 is more or less susceptible to oxidant 
species generated during aPDT.  
 
While all types of viruses can be neutralized by aPDT, the inactivation efficiency depends on 
both the PS and the virus [60,61]. As a rule of the thumb, RNA-type phages are more easily 
photoinactivated than their DNA-type counterparts, suggesting that SARS-CoV-2, which is an 
enveloped RNA-type virus, can be easily neutralized by aPDT [61,62]. Guanine bases are the 
major targets for oxidation by photosensitizing agents in both RNA and DNA [63]. The 
formation of RNA-protein crosslinks may also be an important lesion involved in virus 
inactivation via aPDT [64].  
 
Enveloped viruses are more prone to aPDT neutralization than those without an envelope, due 
to the role of PS in damaging envelope components [65,66]. Initial studies on viral inactivation 
by aPDT demonstrated the importance of the PS reaching specific reaction sites, so-called 
“marked targets”, for efficient viral inactivation [67]. Other reports have confirmed the 
importance of PS binding on efficient virus inactivation via aPDT, and the PS membrane 
partition coefficients can be used as a predictor of its virus inactivation efficacy [68,69]. 
Transmission electron microscopy data has revealed that low PS concentrations degrade 
envelope surface glycoproteins blocking virus internalization, while higher PS concentrations 
can destroy lipid membranes [70]. These results can be interpreted in terms of the current 
mechanistic understanding of photosensitized oxidation, specifically the important role of 
direct-contact reactions. Irreversible membrane damage occurs with the abstraction of a 
hydrogen atom from an unsaturated fatty acid by direct reaction with the triplet excited state of 
the PS. Subsequent formation of peroxyl and alkoxyl radicals leads to the build-up of truncated 
lipid aldehydes, which are ultimately responsible for opening membrane pores [71]. The fact 
that irreversible damage occurs due to contact-dependent reactions, indicates that the damage 
can be confined within the nanometer location site of the PS [72].  
 
In terms of the application of aPDT to treat COVID-19 patients, it is encouraging to note that 
this technique is already used to treat several respiratory diseases [73]. PDT has been used for 
decades to treat lung cancers and its successful application in the treatment of laryngeal 
papillomas has also been reported [74]. Geralde et al. recently demonstrated that acute 
pneumonia caused by Streptococcus pneumoniae could be treated via inhalation of indocyanine 
green combined with extracorporeal administration of infrared light [75]. A prophylactic 
approach proposed by Soares et al. showed that aPDT can also be used to eliminate bacterial 
biofilms frequently associated with endotracheal tubes and that can lead to more severe stages 
of acute respiratory syndromes [76].  
 
Considering that: 1) SARS-CoV-2 is an enveloped RNA virus, 2) aPDT is efficient at 
neutralizing such viruses, and 3) light is already used to treat lung and airway-related infections, 
we propose that aPDT is a good candidate for treating COVID-19 or as an adjunct to disinfect 
biological fluids. Alternatively, photosensitizers could also be used to decontaminate liquids 
and surfaces or be incorporated into polymeric matrices such as plastics, fabrics, paper, and 
paints to produce photoantimicrobial materials [50,55,77]. Allotropes of carbon such as 
fullerenes, carbon nanotubes, and graphene can also show light-activated antimicrobial effects, 
including the inactivation of viruses [66,78,79]. 
 
7. Antimicrobial Blue Light  
 
Visible blue light exhibits microbicidal effects in the wavelength range of 405–470 nm [25,80-
84]. Accordingly, antimicrobial blue light (aBL) has been explored in the treatment of 
infectious diseases and as a disinfection adjuvant in healthcare settings. Clinical trials have 
revealed the efficiency of aBL in the treatment of acne, Helicobacter pylori gastrointestinal 
infections, and dental infections [83,85-87]. aBL was recently shown to rescue mice from 
methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa wound 
infections [88,89]. Oral anaerobic periodontopathogenic bacteria (Porphyromonas gingivalis, 
Prevotella intermedia, and P. nigrescens) were also inhibited or completely eradicated under 
blue light irradiation [90,91].  
 
The exact mechanisms underlying the antimicrobial effects of blue light are not yet completely 
understood but appear to involve the formation of short-lived reactive oxygen species (ROS) 
[92]. The most widely accepted view of the process posits that the photochemical mechanisms 
of aBL are based on light energy excitation of endogenous microbial intracellular light 
receptors (chromophores), such as porphyrins and flavins. Once excited, these receptors 
undergo energy transfer processes that lead to the generation of cytotoxic ROS which react 
with intracellular components resulting in photodamage and cell death by oxidative stress [93]. 
Since endogenous photoreceptors appear to be absent in viruses, the mechanisms by which 
aBL affects these pathogens remains unclear. However, it is currently known that: 1) the use 
of exogenous photosensitizers improves the efficiency of inactivation by blue light, and 2) the 
inactivation is more pronounced when the virus is present in body fluids, e.g., saliva, feces, 
and blood plasma [94,95].  
 
High-intensity narrow-spectrum light at 405 nm has been used for continuous decontamination 
of inpatient and outpatient burn units and patient-occupied intensive care isolation rooms, as 
well as the treatment of surgical site infections in an orthopedic operating room [96-98]. 
Compared to UV-C light, aBL displays decreased deleterious effects on eukaryotic cells, 
reducing the possibility of human tissue injury. While one should avoid direct eye exposure to 
light in this spectral region because the eye lens absorbs visible radiation, aBL can be used in 
human-occupied environments. Additionally, aBL exposure of an elastomeric material did not 
degrade the material’s properties and prevented bacterial adhesion to the material [99].  
 
In a recent bioinformatics study, SARS-CoV-2 was reported to be dependent on porphyrins, 
which it captures from human hemoglobin, resulting in altered heme metabolism [100]. 
However, the in silico methods used to obtain such results have been questioned by a 
commentary publication, putting into doubt wheter SARS-CoV-2 actually interacts with heme 
metabolism and accumulates porphyrins [101]. If this thesis is experimentally proven to be 
correct, aBL might be able to kill SARS-CoV-2 by photoexcitation of its acquired porphyrins. 
Thus, potential applications of aBL to prevent and control COVID-19 may include the 
disinfection aerosols, surfaces and health care PPE.  
 
8. Photobiomodulation Therapy 
 
Photobiomodulation (PBM) employs low levels of red or near-infrared (NIR) light to treat and 
heal wounds and injuries, reduce pain and inflammation, regenerate damaged tissue, and 
protect tissue at risk of dying [102]. Instead of directly targeting viruses, PBM mainly acts on 
the mitochondria, the cell’s powerhouses, which absorb light in the red and near-infrared 
spectral region [103]. The photons are absorbed by chromophores present in the mitochondria. 
Cytochrome c oxidase (i.e., unit IV in the respiratory chain) appears to play the main role in 
this process. Other molecular chromophores include light and heat-sensitive ion channels 
(transient receptor potential) that, upon light activation, lead to changes in calcium 
concentrations. Nanostructured water (interfacial water) is also likely to act as a chromophore. 
Upon irradiation, the mitochondrial membrane potential is raised and oxygen consumption and 
ATP generation are increased. Subsequent activation of signaling pathways and transcription 
factors leads to fairly long-lasting effects even after relatively brief exposure of the tissue to 
light.  
 
In the early 1900s, Finsen reported that patients exposed to red light exhibited significantly 
better recovery from smallpox infections than unexposed counterparts [21]. Since then, PBM 
has been used in the treatment of acute lung injury, pulmonary inflammation, and models of 
acute respiratory distress syndrome (ARDS), due to its ability to substantially reduce systemic 
inflammation while preserving lung function. [104-106]. There are currently 90 published 
papers on PBM concerning “acute lung injury” [106] OR “pulmonary inflammation” [107] OR 
“lung inflammation” [105] OR “ARDS” [108] OR “pneumonia” [109] OR “lung oxidative 
stress” [110] OR “asthma” [111] many involving small animal models where it can be argued 
that light penetrates more easily than in humans. However, there is a significant systemic effect 
of PBM, where absorption of light by circulating blood leads to major biological effects in 
distant parts of the body [112]. Because COVID-19 involves a “cytokine storm”, PBM 
delivered to the torso (chest and back) might not only allow some light to reach the lungs but 
might also reduce the systemic inflammation responsible for COVID-19 sepsis-like syndrome 
[113] and disseminated intravascular coagulation [114] that can be deadly [115]. Moreover, 
PBM is more effective on hypoxic cells [116], suggesting it could be effective for COVID-19 
infection, which seems to be characterized by severe hypoxia [117]. 
 
Hospitalized patients receiving mechanical ventilation or under high-oxygen continuous 
positive airway pressure (CPAP) treatment could be placed on an LED pad. These do not 
generate unacceptable levels of heat, so the high fever experienced by these patients should not 
be a problem. LED-based PBM devices similar to these have been approved by the FDA for 
general health and wellness applications, and there are no reported adverse effects [118]. 
 
9. Ultrafast Laser Irradiation 
 
Ultrashort pulse lasers (USPLs) emitting visible to near-infrared light have been used to 
inactivate a broad spectrum of viruses (human immunodeficiency virus, human papillomavirus, 
encephalomyocarditis virus, M13 bacteriophage, tobacco mosaic virus, and murine 
cytomegalovirus) with no damage to human or murine cells [119-124]. Regardless of 
wavelength, ultrafast laser irradiation does not promote ionization effects that could impair 
host cells. This irradiation does not appear to destroy either bovine serum albumin or single-
stranded DNA, nor cause adverse effects like those produced by toxic or carcinogenic 
chemicals. Previous works suggest that the antimicrobial effect of USPLs is exerted via 
impulsive stimulated Raman scattering, whereby high-frequency resonance vibrations provoke 
vibrations of sufficient strength to destroy the capsid [122,123].  
 
However, laser pulsing may not be necessary for its antimicrobial action. Recently, Kingsley 
et al. applied a tunable mode-locked Ti-Sapphire laser emitting femtosecond pulses at 
wavelengths of 400, 408, 425, 450, 465, and 510 nm to verify inactivation of murine norovirus 
(MNV) [92]. Continuous-wave (CW) lasers were also used. More than 99.9 % of virus 
inactivation was reported after irradiation with an average power of 150 mW at wavelengths 
of 408, 425, or 450 nm femtosecond-pulsed light for 3 hours, indicating that the inactivation 
mechanism is not wavelength-specific. Further, irradiation using a CW laser of similar power 
at 408 nm resulted in a considerable reduction in MNV numbers, suggesting that inactivation 
does not require pulsing.  
 
Other applications for USPLs include their use for pathogen reduction in blood and whole 
inactivated virus vaccines [124,125]. Laser treatment resulted in 1-log, 2-log, and 3-log 
reductions in hepatitis A, human immunodeficiency, and murine cytomegalovirus, respectively, 
in human plasma with no changes in the structure of fibrinogen. [125]. Further, in mice USPL-
induced inactivation of H1N1 influenza virus was more effective than formalin and did not 
cause damage to surface proteins or resulted in the production of carbonyl groups in proteins 
[126].  
 
10. Concluding remarks  
 
In summary, we have described how light-based strategies can be used to reduce SARS-CoV-
2 transmission through air, water, and surfaces as well as potential therapeutic applications that 
can reduce its morbidity and mortality. From our perspective, light provides several practical 
answers to the new logistical and therapeutic challenges brought by COVID-19. Therefore, we 
suggest that the death toll and quarantine extent can be significantly mitigated if at least part 
of these strategies are encouraged and implemented by health systems. Given the urgent 
demand raised by the current uncontrolled pandemic we must be ready to use all the available 
armamentarium to fight COVID-19. 
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Figure 1. Mechanisms of photosensitized oxidation reactions. The photosensitizer (PS) is a 
molecule capable of absorbing light depending on its specific absorption spectra. Once excited, 
the PS is converted from the ground state 1PS to its singlet excited 1PS* and triplet excited 3PS* 
states. Via Type I (contact-dependent) reactions both 1PS* and 3PS* can react directly with O2 
or biomolecules, like carbohydrates, lipids, proteins, or nucleic acids, resulting in the formation 
of radicals capable of initiating redox chain reactions. Otherwise, 3PS* can react with molecular 
oxygen (3O2), via the Type II (energy transfer) reaction, generating the reactive state of singlet 
oxygen (1O2).  
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